Minerva Neurosciences, Inc: Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Fri, 7 August 2026
What it is about
Minerva NeurosciencesRichtung AllzeithochCorey DavisKorrektur FahrtStefan LeuchtRemy LuthringerJonathan RabinowitzGlobenewswire EuropeMichael DavidsonChristoph CorrellFrederick AhlholmTechnical University Of MunichLifesci AdvisorsNasdaqBoehringer IngelheimExchange CommissionUnited StatesDepartment Of PsychiatryMunich, Bayern, GermanyAmerica
Who published it, and when
How it spread - 1 original report
Fri, 7 August 2026
1 report- finanznachrichten.de13:10first to report
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to